Evidence map›Paper›PMID 23613156›Full record

ArticleJournal of biomedical materials research. Part A2013

Fabrication and in vivo thrombogenicity testing of nitric oxide generating artificial lungs.

Kagya A Amoako, Patrick J Montoya, Terry C Major, Ahmed B Suhaib, Hitesh Handa, David O Brant, Mark E Meyerhoff, Robert H Bartlett, Keith E Cook

Open access · greenAbstract read
In one paragraph

Article in Journal of biomedical materials research. Part A, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Bioengineering Progress in Lung Assist Devices.Bioengineering (Basel, Switzerland) · 2021
    Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Fourteen Day In Vivo Testing of a Compliant Thoracic Artificial Lung.ASAIO journal (American Society for Artificial Internal Organs : 1992)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Kagya A AmoakoDepartments of Surgery, University of Michigan Medical Center, 1150 W Medical Center Drive B560B MSRBII, Ann Arbor, MI 48109-0686; Department of Internal Medicine, Cardiology, University of Michigan Medical Center; Department of Chemistry, University of Michigan, Ann Arbor, MI.
Patrick J Montoya
Terry C Major
Ahmed B Suhaib
Hitesh Handa
David O Brant
Mark E Meyerhoff
Robert H Bartlett
Keith E Cook
University of Michigan–Ann Arbor · USAnn Arbor VA Medical Center · US

Funding

Pediatric Implantable Artificial LungR01HD015434 · NICHD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HIRSCHL, RONALD BRUCE · 1985 to 2021
$10.8M
Development of a Total Artificial LungR01HL069420 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BARTLETT, ROBERT H. · 2002 to 2011
$10.1M
Compliant Thoracic Artificial LungsR01HL089043 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COOK, KEITH E · 2009 to 2017
$4.2M
NHLBI NIH HHS 2R01 HL069420-06NHLBI NIH HHS R01 HL069420NHLBI NIH HHS R01 HL089043NICHD NIH HHS R01 HD015434
6 · The paper itself

Abstract

Hollow fiber artificial lungs are increasingly being used for long-term applications. However, clot formation limits their use to 1-2 weeks. This study investigated the effect of nitric oxide generating (NOgen) hollow fibers on artificial lung thrombogenicity. Silicone hollow fibers were fabricated to incorporate 50 nm copper particles as a catalyst for NO generation from the blood. Fibers with and without (control) these particles were incorporated into artificial lungs with a 0.1 m(2) surface area and inserted in circuits coated tip-to-tip with the NOgen material. Circuits (N = 5/each) were attached to rabbits in a pumpless, arterio-venous configuration and run for 4 h at an activated clotting time of 350-400 s. Three control circuits clotted completely, while none of the NOgen circuits failed. Accordingly, blood flows were significantly higher in the NOgen group (95.9 ± 11.7, p < 0.01) compared to the controls (35.2 ± 19.7; mL/min), and resistance was significantly higher in the control group after 4 h (15.38 ± 9.65, p < 0.001) than in NOgen (0.09 ± 0.03; mmHg/mL/min). On the other hand, platelet counts and plasma fibrinogen concentration expressed as percent of baseline in control group (63.7 ± 5.7%, 77.2 ± 5.6%; p < 0.05) were greater than those in the NOgen group (60.4 ± 5.1%, 63.2 ± 3.7%). Plasma copper levels in the NOgen group were 2.8 times baseline at 4 h (132.8 ± 4.5 μg/dL) and unchanged in the controls. This study demonstrates that NO generating gas exchange fibers could be a potentially effective way to control coagulation inside artificial lungs.

Indexed as

Artificial OrgansAnimalsBlood Cell CountBlood PlateletsCopperFibrinogenHemodynamicsLungNitric OxideRabbitsRegional Blood FlowS-NitrosothiolsThrombosisTime FactorsTissue EngineeringCopperFibrinogenNitric OxideS-Nitrosothiolsartificial lungbiocompatibilityextracorporeal circulationnitric oxidesiliconethrombosis

Identifiers

PMID23613156
PMCPMC3812367
OpenAlexW1853899972

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.